We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 2,164

Is your Employee NDA Weak?
  • Foley & Lardner LLP
  • USA
  • June 8 2017

We live in a world of “leaking” information and the automotive industry is not immune. Automotive companies go to great lengths to protect their


Supreme Court Biosimilar Patent Dance Decision Largely Favors Biosimilars
  • Foley & Lardner LLP
  • USA
  • June 13 2017

On June 12, 2017, the Supreme Court issued a unanimous decision in Sandoz Inc. v. Amgen Inc. (No. 15-1039), deciding that 42 U.S.C. 262(l)(9)(C


Supreme Court Decision Largely Favors Biosimilar Applicants
  • Foley & Lardner LLP
  • USA
  • June 12 2017

The U.S. Supreme Court rendered its first interpretations of the biosimilar patent dispute resolution procedures of the Biologics Price Competition


Utilizing California Civil Code Section 1542 Waivers in Class Action Settlement Agreements: Helpful or Harmful?
  • Foley & Lardner LLP
  • USA
  • June 12 2017

A significant concern for any lawyer negotiating the settlement of a class action in California state court is crafting a settlement agreement that


SEC and U.S. Attorney’s Office Continue Their Pursuit of Criminal Actions Against Purveyors of “Political Intelligence”
  • Foley & Lardner LLP
  • USA
  • June 9 2017

On May 24, 2017, the United States Attorney’s Office for the Southern District of New York and the Securities and Exchange Commission (SEC) launched


Non-Competes Can Cost You More Than A Job
  • Foley & Lardner LLP
  • USA
  • June 5 2017

Normally in this space we write about case developments after the case is decided. This time, though the story involves a mid-case development which


State Attorneys General Warn the EPA of Legal Action Should Obama-Era Fuel Economy Standards Get Rolled Back
  • Foley & Lardner LLP
  • USA
  • June 15 2017

Even as the Trump administration is calling into question whether it will remain committed to Obama-era fuel economy and emissions targets, state


Industry Perspectives On The Biosimilar Patent Dance
  • Foley & Lardner LLP
  • USA
  • June 12 2017

The Supreme Court could issue its decision in the Amgen v. Sandoz biosimilar patent dance case any day now. Last week I participated in a panel


Federal Circuit’s Primer on Equivalence Infringement of Chemical Process Patents
  • Foley & Lardner LLP
  • USA
  • May 21 2017

In an appeal characterized as “unusual,” the Federal Circuit affirmed the grant of a preliminary injunction, holding it likely that plaintiff patent


CFPB Settlements: It’s Not Over Until It’s Over
  • Foley & Lardner LLP
  • USA
  • May 10 2017

On April 26, 2017, the Consumer Financial Protection Bureau (“CFPB”) broke new ground by imposing a fine - in excess of a million dollars - against a